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Abstract 
Background: The management of Dengue virus infection can be challenging. Varied presentations and numer-
ous complications intrinsic to dengue by itself increase the complexity of treatment and potential mortality. When 
burdened with the presence of additional comorbidities and the need to continue compulsory medications, clear 
stepwise definitive guidance is lacking and patients tend to have more complex complications and outcomes calling 
to question the clinical decisions that may have been taken. The use and continuation of warfarin in dengue virus 
infection is one such example.
Case presentation: We report a 65 year old South Asian female who presented with dengue fever. She had a history 
bronchial asthma, a prior abdominal surgery, and was on warfarin and maintained a therapeutically appropriate inter-
nationalized normalized ratio for a mechanical aortic valve replacement. Though preemptive decision to stop warfarin 
was taken with decreasing platelet counts, her clinical course was complicated with the development of bilateral 
rectus sheath haematoma’s requiring resuscitation with blood transfusions.
Conclusion: Though management of dengue viral fever has seen drastic evolution with recent updated guid-
ance, clinical scenarios seen in the course of the illness still pose challenges to the managing physician. The need to 
continue obligatory anticoagulation which may seem counterintuitive during a complex disease such as dengue 
virus infection must be considered after understanding the potential risks versus that of its benefits. Though case by 
case decisions maybe warranted, a clear protocol would be very helpful in making clinical decisions, as the correct 
preemptive decision may potentially avert catastrophic and unpredictable bleeding events.
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Background
Dengue viral fever has taken pandemic proportions as 
nearly half of the world’s populace is at risk [1], and rapid 
global urbanization ensures the further increased spread 
and scourge of this potentially deadly mosquito borne 
viral infection. The advent of a live attenuated tetravalent 
vaccine gives hope for the future with proven efficacy 
against virologically confirmed dengue [2]. But it may 
still be awhile before its impact is felt. Adoption has been 
slow with Philippines taking the initiative to introduce 
dengue vaccine into its public health initiative in April 
2016, though amidst controversy. Dengue viral fever is 
renowned for its propensity to cause capillary leakage 
resulting in dengue haemorrhagic fever with resultant 
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morbidity and mortality. The rarer variants of presenta-
tions are being recognized and categorized separately as 
dengue expanded syndrome [3]. Bleeding, however is a 
well-known complication of dengue and has been recog-
nized in its varied possible phases of the disease includ-
ing in dengue fever by itself in the absence of capillary 
leakage, during dengue haemorrhagic fever and dengue 
shock [4]. Though cautious fluid balance and replacement 
is the cornerstone of management in minimizing morbid-
ity and mortality [1], the lack of consistency in the pat-
tern of presentation and progression of the disease can 
still pose a challenge in management, even in normal cir-
cumstances for the skilled physician. When complicated 
with single organ involvement, bleeding or compounded 
with the burden of managing additional co-morbidities 
requiring complex simultaneous management, takes an 
already challenging situation into unknown territory, 
with little in the way of evidence based guidance. The use 
or continuation of anticoagulation in mandatory situa-
tions is one such example and the lack of clear guidance 
with regard to anticoagulation in dengue management 
protocols and guidelines have been noted [5]. In this case 
vignette we present and discuss a patient who required 
lifelong anticoagulation due to mechanical aortic valve 
replacement who presented with dengue fever and suf-
fered complicated bleeding which posed significant chal-
lenges in regard to clinical decisions and management.
Case presentation
A 65 year old South-Asian female presented to the medi-
cal ward with an acute febrile illness with characteristic 
prodromal symptoms on day 1 of her illness. Being an 
endemic country to dengue viral infection, clinical suspi-
cion made us prioritize our investigations and a positive 
dengue NS1 antigen confirmed dengue viral infection. 
She had a significant past history of symptomatic aortic 
stenosis which necessitated surgery and had undergone 
mechanical aortic valve replacement in 1999. She was 
on oral warfarin and had maintained a therapeutically 
appropriate internationalized ratio (INR) while on 5 mg 
with no prior episodes of significant bleeding. She addi-
tionally gave a history of hypertension with dyslipidemia 
and was also an asthmatic on medical management with 
good compliance. She also had a notable obstetric past 
history which had required a classical caesarean section.
Preliminary examination revealed a normotensive 
patient with a blood pressure of 130 mmHg systole and 
80 mmHg diastole and had a regular pulse of 92 beats per 
minute. Cardiac auscultation revealed a mechanical click 
coinciding with 2nd heart sound and an ejection systolic 
murmur favoring a functional mechanical aortic valve in 
the absence of any other findings favoring decompensa-
tion. Though respiratory examination revealed scattered 
bilateral rhonchi, the patient appeared stable with a res-
piratory rate of 16 breaths per minute. Abdominal exami-
nation revealed a midline scar keeping in with the history 
of a classical caesarean section. Neurological examina-
tion was unrevealing. A decision was taken to continue 
her routine metered dose inhalers of salmeterol and flu-
ticasone 250/50 micrograms twice daily. Additionally she 
was also nebulized 8 hourly with oxygen driven salbuta-
mol. Though she had been on oral losartan 50 mg bd for 
her hypertension and rosuvastatin 10  mg nocte for her 
dyslipidemia a clinical decision was taken to discontinue 
both. However in consideration of her mechanical aortic 
valve, we took the clinical decision to continue her warfa-
rin without dose reduction at 5 mg vesper.
On admission, which was day 1 of her illness, whole 
blood analysis revealed a hemoglobin of 9.3  g/dL (11–
15) with a low total white cell count of 3.89  ×  109/L 
(4–11) and a platelet count of 113  ×  109/L (150–450). 
Her INR was 2.7 (<1 normal and target range of 2–3 in 
her situation). Warfarin was cautiously continued while 
judiciously following her drop in platelet counts with fre-
quent whole blood analysis. Her liver functions showed 
a mild but acceptable derangement of transaminases 
with an aspartate transaminase of 144 (<35 IU) and ala-
nine transaminase of 62 (<40  IU) with a normal refer-
ence range for activated thromboplastin time. On day 4 
of her illness when her platelet count dropped to below 
50 × 109/L (150–450), warfarin was stopped and a clini-
cal decision was taken to change over to intravenous 
unfractionated heparin (at 1000  IU/h) as the anticoagu-
lant of choice to ensure continued anticoagulation for 
her mechanical heart valve. She was closely monitored 
with activated partial thromboplastin time (APTT) at 
six hourly intervals. However, a rapid and unexpected 
prolongation of APTT to  >200  s (<40  s) prompted us 
to reconsider continuation of heparin and decision was 
taken to transiently withhold heparin. During this period 
she was neither symptomatic nor had clinically evident 
signs of bleeding or its manifestations. She was continu-
ously monitored and on day 6 her platelets continued 
to drop to its lowest nadir of 27 × 109/L (150–450). Her 
deranged APTT had normalized by this point and were 
within normal reference parameters.
On day 7 of illness with an already rising platelet count 
of 50 × 109/L (150–450), and normal coagulation param-
eters (an INR of 1.1 and APTT of 35 s) she complained 
of a continuous lower abdominal pain. However clinical 
examination was unrevealing. While still being moni-
tored with frequent whole blood analysis an observation 
was made of a drop in both haemoglobin and haemato-
crit from 9.3 g/dL (11–15) to 7.9 g/dL (11–15) and from 
33 (35–45) to 27 (35–45) respectively, which also coin-
cided with a notable drop in her urine output (<0.5  cc/
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kg/h) which had maintained till then. Despite a tachycar-
dia of 110 beats per minute her blood pressure remained 
within acceptable parameters, suggesting compensated 
shock. A possible intra-abdominal bleed was suspected. 
Ultrasonographic examination revealed a right sided 
rectus sheath haematoma measuring 13 mm by 15 mm. 
There were however no features to favor dengue haem-
orrhagic fever as features of fluid leakage were absent 
ultrasonographically. Failure of the parameters to cor-
rect, prompted us to do a follow up ultrasound abdo-
men which confirmed the extension of the haematoma 
on the right to 71 mm by 53 mm with a new haematoma 
forming on the contralateral left side as well, measuring 
33 mm by 23 mm (Fig. 1). No further bleeding sites were 
identified. Additional occult bleeding was suspected and 
based on haematological and haemodynamic parameters, 
she was initially volume resuscitated with normal saline 
and to err on the side of caution she was also transfused 
with 3 units of packed red cells to achieve stabilization 
and counteract blood loss. Post transfusion haemoglobin 
was 10.1 g/dL (11–15) and haematocrit was 34 (35–45). 
A decision was taken not to transfuse fresh frozen plasma 
or platelets as tested coagulation parameters (APTT & 
INR) were normal, and platelet counts were 50 × 109/L 
(150–450) and rising. With defervescence of tempera-
ture and rising platelets, her haematological parameters 
stabilized and intensive monitoring was continued. After 
72 h of clinical stability she was started on oral anticoag-
ulation and bridged with low molecular heparin until the 
INR reached acceptable therapeutic range. The patient 
thereafter made an uncomplicated recovery.
Conclusions
Dengue viral fever has a myriad of presentations and 
complications. Bleeding is an acknowledged and notori-
ous complication of dengue. Through complex patho-
physiological mechanisms dengue fever can impact the 
risk and cause bleeding in many ways. Hypothesis have 
been put forward questioning the role of hematologi-
cal disturbance through thrombocytopenia and platelet 
dysfunction, to low fibrinogen and factors involved in 
the coagulation cascade resulting in prolonged APTT. 
Hepatic dysfunction and coagulopathy worsened by dis-
seminated intravascular coagulation and even vasculopa-
thy are thought to possibly contribute towards bleeding, 
aided by the immunological disturbance seen in dengue 
viral fever [6–8]. When coupled together with use of 
either anti-platelet’s or anticoagulation the theoretical 
risk of bleeding is exponentially worse.
Warfarin is one of the most commonly used anticoagu-
lants due to affordability, availability and proven efficacy. 
The factors that contribute towards bleeding are many 
and the risk differs on individual basis. But overall the 
risk of bleeding is greatest when initiating warfarin, or if 
the dose was supra-therapeutic, if there were drug inter-
actions and when complicated with an ongoing illness. 
In fact a dose reduction is advised during inter-current 
illness. Advancing age is another confounding factor and 
there is still uncertainty whether it acts as an independ-
ent factor. Additionally when burdened with chronic dis-
eases such as hypertension and renal insufficiency, the 
likelihood of bleeding is even greater when using warfa-
rin [9, 10].
Bleeding can occur in any part of the body when using 
anticoagulation. Rectus sheath haematoma is a rare yet 
observed complication of anticoagulation [11]. Bilateral 
rectus sheath haematoma is an even rarer occurrence 
with few documented cases in literature [12–14]. Rectus 
sheath haematoma is commonly seen in women more 
than men and specially in their 6th to 7th decades of life 
[15]. The risk of developing rectus sheath haematoma 
is greater when having a background history of trauma, 
Fig. 1 Image depicts the ultrasound findings which reveal a right 
sided hypo-echoic lesion (upper image) within the rectus sheath 
measuring 71 mm by 53 mm (depicted by cross hairs) and similar 
lesion within the left side rectus (lower image) sheath measuring 
33 mm by 23 mm (depicted by cross hairs)
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straining, coughing, pregnancy and abdominal surgery 
[16]. Rarely, rectus sheath haematomas have also been 
documented complicating dengue viral fever [14, 17]. 
Though conservative management is adequate in most 
circumstances with the cessation of anticoagulation, 
when complicated with haemodynamic instability sup-
portive care coupled with blood transfusion may become 
necessary [11, 15]. Thus having awareness and main-
taining a high index of suspicion in appropriate clinical 
circumstances is paramount for the early and accurate 
diagnosis of rectus sheath haematoma. This will result in 
the opportunity for quick institution of appropriate treat-
ment measures, with improved outcome [18].
There are obligatory conditions where the use of anti-
coagulation is essential and needs to be continued as the 
benefit outweighs the potential risks. When bleeding 
occurs the choice of discontinuing or reducing oral anti-
coagulation depends on whether the episode was a major 
or minor event [19]. When compounded with an ongo-
ing dengue viral infection the decision to continue anti-
coagulation challenges the physician to reassess its need. 
However a definitive clinical event such as an established 
bleed while having dengue viral fever may simplify the 
difficult clinical decision of stopping anticoagulation out 
of necessity.
In the absence of either obvious or occult bleeding, 
the clinician may choose to cease anticoagulation in the 
presence of dropping platelet counts to err on the side of 
caution. The point at which this has to be done should 
be decided on a case by case basis. The lowest threshold 
of absolute platelet count considered safe has varied, but 
usually lies between the range of 50 × 109/L (150–450) to 
100 ×  109/L (150–450) [5, 20]. The safe limit suggested 
to reinitiate anticoagulation is when platelet counts rise 
above 50 × 109/L (150–450) [5, 20].
The possible justifications to argue in favor of this 
course of action are twofold. Foremost in the presence of 
life threatening bleeds, anticoagulation should be discon-
tinued even in obligatory circumstances. In such situa-
tions anticoagulation has been discontinued as long as by 
a week, and sub-therapeutic levels have been maintained 
even further successfully with minimal thromboembolic 
risk [5]. Additionally the annual risk of thrombosis with 
mechanical valves even without anticoagulation is only 
20% [8] and thus may justify the decision. The second 
consideration being is the persistence of anticoagulation 
to a certain degree even following cessation. In average 
it takes 2–3 days for the INR to drop below 2, and nearly 
4–6 days for it to normalize [21]. The single most impor-
tant factor that determines this is the initial baseline INR 
level [22]. Based on this, even a higher level platelet count 
could be justified when stopping warfarin if the INR 
is inappropriately elevated at the outset. Thus a level of 
anticoagulation being present even following cessation 
may offer some degree of protection and theoretically 
grants a few days of bargaining time. That being said, the 
drop in platelet counts in dengue fever is also quite vari-
able, and hard to predict as significant drop occurs in 3rd 
to 4th day of fever and the counts keep decreasing to an 
average of 7 days [23].
Despite all of this there is still disagreement as to if 
bleeding is associated with thrombocytopenia, even 
when very severe [7, 23]. The problem is further com-
pounded by the fact that bleeding in dengue viral fever is 
probably multifactorial as mentioned above, and choos-
ing only absolute platelet counts, whatever the count 
value as a sole criterion to stop and restart anticoagula-
tion may in fact be an arbitrary decision, as it happens to 
be the easiest one to monitor.
The patient along with their primary need of anticoagu-
lation and their associated comorbidities should be taken 
into consideration when making the clinical decision to 
cease anticoagulation. To achieve this, patients can be 
risk stratified. A higher risk is present when the need is 
following mechanical valve replacement, and more so if 
the replacement involves multiple valves. A prior history 
of thromboembolic episodes and having added comor-
bidities increases one risk (e.g. diabetes, hypertension 
or prior stroke), and places an individual into a high risk 
category as well. In such situations withholding warfarin 
and substituting heparin when INR becomes sub-thera-
peutic and omitting all forms of anticoagulation when 
platelets drop below 50 × 109/L (150–450) or even ear-
lier in advanced forms of presentation of dengue spec-
trum with events of either bleeding or shock have been 
suggested. Alternatively when having low risk factors e.g. 
chronic atrial fibrillation with minimal risk factors, con-
sider omitting warfarin to err on the side of caution by 
as much as one week without having stringent criteria is 
preferred [8, 24].
Our patient had all the classic and added risk factors 
needed to develop this rare yet potentially lethal compli-
cation, including cough secondary to bronchial asthma, 
prior abdominal surgery and distorted anatomy and 
developing dengue viral fever while being on warfarin. 
The fact that we preemptively stopped anticoagulation 
(both warfarin and unfractionated heparin) due to her 
high risk status, and her coagulation parameters being 
normal at the point in time of her haemorrhage points 
towards another cause, other than the anticoagula-
tion as the cause for her to have bled. Thrombocytope-
nia though attributable to dengue viral fever could also 
have rarely resulted from heparin, in the form of heparin 
induced thrombocytopenia (HIT), type 1. However, HIT 
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is predominantly pro-thrombotic and thus the propensity 
to bleed in the presence of thrombocytopenia favors den-
gue more than that of HIT. Though her other risk factors 
may have played a role in contributing towards the result-
ant bleed, one should strongly consider the role dengue 
viral fever had to play. Considering the event in question 
occurred during convalescence as commonly observed 
in other case reports of similar nature with significant 
bleeding [14], we can possibly assume that dengue viral 
fever through its complex mechanism may have been the 
primary cause for her to have bled.
The decision to continue or stop anticoagulation may 
never be an easy choice to make in dengue viral infection 
unless complicated with a bleeding event. In the absence 
of which a patient based risk stratification should be done 
considering all relevant information including the need 
for anticoagulation and any associated comorbidities that 
may inadvertently facilitate the risk of bleeding. Making 
the correct decision to stop anticoagulation in a timely 
manner may potentially help prevent catastrophic bleed-
ing events considering the highly unpredictable nature 
of dengue viral infection and its propensity to cause 
bleeding in different phases of illness through complex 
mechanisms.
The clinical management of patients with dengue viral 
fever on mandatory anticoagulation is difficult, as the 
decision to continue or cease warfarin compels the phy-
sician to weigh the risks intrinsic to dengue fever versus 
that of lack of anticoagulation. There is limited guid-
ance, and even the available guidance is based on case 
reports and extrapolations from similar clinical scenar-
ios. The unpredictable course of dengue viral fever and 
the lack of understanding of the underlying pathophysi-
ological process that predisposes to bleeding in dengue 
viral fever makes even the well thought out decision to 
stop anticoagulation in retrospect to appear arbitrary. 
However based on risk factors, making the correct deci-
sion in a timely manner to withhold anticoagulation can 
potentially avert catastrophic clinical events. Thus it 
should be stressed, if a decision is taken to cease anti-
coagulation in dengue viral fever it should be based on 
a case by case basis considering all relevant risk factors 
and the evolving clinical picture. Though lacking, the 
presence of a clear protocol and guidance would greatly 
aid clinicians when faced with making such difficult 
decisions.
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